-+ 0.00%
-+ 0.00%
-+ 0.00%

DUPIXENT® (DUPILUMAB) DEMONSTRATED SUPERIORITY OVER XOLAIR® (OMALIZUMAB) IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP) IN PATIENTS WITH COEXISTING ASTHMA IN FIRST-EVER PRESENTED PHASE 4 HEAD-TO-HEAD RESPIRATORY TRIAL

Reuters·06/15/2025 15:21:00

Please log in to view news